SCHEMBL1241457

SCHEMBL1241457

Cc1c(F)nc2ccc(Cl)nn2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
TNF P01375 1/20 0.36
DYRK1A Q13627 2/20 0.35
DYRK2 Q92630 2/20 0.35
NPC1 O15118 5/20 0.33
HSD17B10 Q99714 4/20 0.33
CASP1 P29466 3/20 0.33
CASP7 P55210 3/20 0.33
MAPT P10636 3/20 0.33
TP53 P04637 2/20 0.33
RXFP1 Q9HBX9 2/20 0.33
RAB9A P51151 5/20 0.33
TSHR P16473 1/20 0.33
TNKS O95271 1/20 0.32
DYRK3 O43781 1/20 0.32
CCNT1 O60563 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8262886 0.81 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL18335743 0.74 ALDH1A1 (0.39) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL31001942 0.73 KDM4E (0.44) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL18337391 0.72 ALDH1A1 (0.37) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL10854795 0.71 KDM4E (0.56) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL15690003 0.68 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL12798307 0.68 KDM4E (0.47) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL8100877 0.68 SMN1; SMN2 (0.56) ALDH1A1KDM4ESMN1; SMN2NPC1HSD17B10
SCHEMBL31449500 0.67 KDM4E (0.43) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77
SCHEMBL477062 0.66 KDM4E (0.44) ALDH1A1KDM4ESMN1; SMN2PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884104-B2 Such as (3R,4R)-1-Pyrimidin-4-yl-4-(2,4,5-trifluorophenyl)piperidin-3-amine bis-trifluoroacetic acid salt MERCK SHARP & DOHME CORP. (US) 2011-02-08 US disclosed
EP-1796669-B1 AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK SHARP & DOHME (US) 2010-09-22 EP disclosed
US-20080076773-A1 Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes MERCK SHARP & DOHME LLC 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076773-A1 Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes DPP4, DPP3, DPP7 ALDH1A1 1070/4885KDM4E 571/4885SMN1; SMN2 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.